<DOC>
	<DOCNO>NCT01438138</DOCNO>
	<brief_summary>RATIONALE : A screening test , My Profile Pediatric Assay , may help doctor predict patient 's risk relapse plan well treatment acute myeloid leukemia . PURPOSE : This clinical trial study use My Profile Pediatric Assay see well work predict risk relapse bone marrow cell sample young patient acute myeloid leukemia .</brief_summary>
	<brief_title>Study Predict Risk Relapse Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To validate accuracy My Profile Pediatric Assay predict risk relapse pediatric patient non-M3 acute myeloid leukemia ( AML ) respond cytarabine-based induction chemotherapy . Secondary - To validate continuous score pre-specified classifier predictor relapse response induction chemotherapy , control simultaneous effect follow clinical laboratory variable : age , WBC , ethnicity , cytogenetics , Flt3-ITD , NPM1 , MRD , bone marrow ( BM ) donor availability . - To validate accuracy prespecified low versus high relapse indicator variable ( I_L/H ) predictor relapse induction therapy . - To validate accuracy prespecified I_L/H predictor relapse induction therapy , control simultaneous effect follow clinical laboratory variable : MRD , age , WBC , ethnicity , cytogenetics , Flt3-ITD , NPM1 , BM donor availability . OUTLINE : Archived bone marrow mononuclear cell analyze single cell network profile assay , My Profileâ„¢ AML Risk Relapse Assay . Molecular marker analyze include Flt3-ITD , NPM1 , MRA . Results correlate patient 's clinical data include patient 's age , race/ethnic background , gender , treatment receive , outcome .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients confirm nonM3 acute myeloid leukemia Treated COGAAML03P1 COG AAML0531 protocols Samples COGAAML0531 come either treatment arm , sample need independent patient donate sample assay study COGAAML11B2 Patients Down syndrome exclude Cryopreserved bone marrow mononuclear cell ( BMMC ) sample collect diagnosis , prior start induction therapy Samples must cryopreserved central lab within 3 day draw clinical site Target 10 X 10^6 cell frozen Patients ' clinical annotation require unblinding PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood acute basophilic leukemia</keyword>
	<keyword>childhood acute eosinophilic leukemia</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>